As of 2026-06-26, Pelthos Therapeutics Inc. (PTHS) has a 3-month relative strength percentile of 79 within the TickerStance CS+ADRC universe (~5,000 tickers). The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 3.6%, relative volume 1.04×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PTHS ranks at the 71th percentile over 1 month, 79th percentile over 3 months, 65th percentile over 6 months against the full TickerStance CS+ADRC universe of U.S. equities.
PTHS is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data.
Sector RS percentile is not available for Healthcare at this snapshot. Leading sector status (threshold: Healthcare RS ≥ 70th percentile) cannot be determined until the next sector RS pipeline run.
PTHS currently shows a 20-day average daily range (ADR%) of 3.6%, a 90-day beta versus the S&P 500 of 0.90. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
TickerStance computes PTHS's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what PTHS has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.
PTHS most recently filed a 10-Q covering FY26 Q1 with the SEC on 2026-05-14. TickerStance sources earnings data from SEC EDGAR XBRL submissions and updates the fundamentals panel daily. The Pro dossier shows eight quarters of EPS and revenue trend, operating margin history, and a composite earnings-quality rank.